DMS IMAGING INTERIM FINANCIAL REPORT
AS OF JUNE 30, 2020
TABLE OF CONTENT | ||
I. | INTERIM MANAGEMENT REPORT .................................................................................................................. | 4 |
1. | CORPORATE INFORMATION .................................................................................................................................... | 4 |
2. | BUSINESS UPDATE.................................................................................................................................................. | 4 |
3. | FINANCIAL UPDATE ............................................................................................................................................... | 5 |
4. | PRINCIPAL RISKS AND UNCERTAINTIES..................................................................................................................... | 6 |
5. | OUTLOOK FOR THE SECOND HALF OF 2020............................................................................................................. | 6 |
- INTERIM CONDENSED IFRS FINANCIAL STATEMENTS FOR THE PERIOD ENDING JUNE 30, 2020 8
1. | MAIN FIGURES....................................................................................................................................................... | 8 |
2. | GENERAL INFORMATION ...................................................................................................................................... | 13 |
3. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ................................................................................................ | 13 |
Basis of preparation.................................................................................................................................... | 13 | |
Significant accounting policies .................................................................................................................. | 14 | |
Significant estimates ..................................................................................................................................... | 14 | |
4. | OPERATING SEGMENT INFORMATION .................................................................................................................... | 16 |
5. | FAIR VALUE......................................................................................................................................................... | 16 |
6. | GOING CONCERN ................................................................................................................................................ | 17 |
7. | R&D AND GENERAL & ADMINISTRATIVE EXPENSES............................................................................................... | 18 |
8. | RELATED PARTY TRANSACTIONS............................................................................................................................ | 18 |
9. | EVENTS AFTER JUNE 30, 2020 ............................................................................................................................. | 19 |
III. | RESPONSIBILITY STATEMENT ................................................................................................................... | 21 |
1. | RESPONSIBILITY STATEMENT ................................................................................................................................. | 21 |
IV. | REPORT OF THE STATUTORY AUDITORS ON THE LIMITED REVIEW OF THE IFRS CONDENSED | |
FINANCIAL STATEMENT .......................................................................................................................................... | 23 |
1
ASIT biotech SA
A limited liability company (société anonyme) incorporated under Belgian law,
with its registered office at 7, rue des Chasseurs Ardennais - 4031 Angleur (enterprise number BE
0460.798.795)
INTERIM FINANCIAL REPORT
AS OF JUNE 30, 2020
This report is prepared in accordance with article 13 of the Royal Decree of November 14, 2007
ASIT biotech SA (hereinafter "ASIT biotech" or the "Company") has prepared its interim financial
report in French and in English. In case of discrepancies between both versions, the English
version shall prevail
2
I. INTERIM MANAGEMENT REPORT
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
ASIT Biotech SA published this content on 30 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2020 16:14:05 UTC
